Cryptocurrencies against cancer

KeyZell is the first biotech to realize a Token Generation Event (TGE) through the project. K2Z Helper IconThe maximum issue will be 2,000 million coins and 200,000 NFTs.

This innovative project aims to issue a useful exchangeable token to service its system. Artificial intelligence for precision medicineand another non-tradable token of industrial property of this AI, christened IP-NFT (Industrial Property-NFT) by KeyZell.

This token issuance will allow them to keep moving forward with their projects. fight against cancer They work in a safe environment because they work under it. blockchain technology.

Global disease status

Searching for a cure for cancer one of the most lucrative jobs on the planet, far superior to technology. Everything counts in the thousands and millions in the fight against cancer. According to the latest research published by the IQVIA Institute, Global Oncology Trends 2021, the global market for treatments for this disease is predicted to reach 2.$69 billion by 2025. The US is led by 42%, followed by five main European markets: Germany, France, Great Britain, Italy and Spain.

Nearly 10 million people died of cancer in 2020, and more than 19 million new cases are added worldwide each year. Unfortunately, every year death estimates are exceeded With the incidence of the International Agency for Research on Cancer and these data, it is not surprising that one out of every three men and one out of every four women will have this disease in their lifetime.

It is also increasing due to the global incidence. population aging and with an increase in risk factors.

TGE at the service of the fight against cancer

KeyZell’s K2Z Utility Token project is a model supported by: Democratization of your industrial property in NFT formatand a company supported by a management and research team of international relevance. This project aims to promote itself among patients and only be a way to reach those who really need it and not just use it as a tool. speculative investment.

NFTs are structured like this: create or create payment on any future transfer of tokens. This type of payment is smart contract It is within the NFT that the issuer can track the following transfers (re-sales) that appear to be registered on the blockchain where the NFT was made.

“KeyZell’s purpose with the token is to personalized treatment diagnosis service against precision medicine cancer and where patients can get new tokens to use with AI every year with NFTs. With this, we want to continue to develop our KeyZell OPS project, which is a tool based on it. machine learning chooses the best treatment for each patient based on their individual characteristics. José de CorralCEO of KeyZell.

The company is waiting to start human clinical trials for the treatment breast and lung cancerIt has an innovative AI system in the commercialization phase, a guarantee of future cash flow generation, and above all a guarantee for investors looking for premium projects like K2Z Token.

Company

KeyZell consists a multidisciplinary group professionals from various fields, researchers from well-known highly prestigious centers such as the University of Seville, the University of Malaga or the Imperial College London, engineers and senior professionals with management experience in large international projects. pharmaceutical, legal and business sectors.

The company is also a highly qualified team of consultantsnot only in the medical or scientific field, but also in intellectual property, legal or strategic matters.

Currently working on KeyZell various lines of researchOn the one hand, it is a new first-line therapy, a treatment in the preclinical phase, against certain types of tumors awaiting the start of a phase I/IIa clinical trial. prevent metastasis.

On the other hand, he is developing the innovative artificial intelligence system KEYZELL OPS, which he already has. industry licenseAiming to be the future of precision medicine in oncology, based on the search for mold and personalized treatment for cancer patients who do not respond to treatment, best treatment for cancerin the appropriate order and at the most appropriate time according to the characteristics of each patient.